AOK Rheinland Pfalz Saarland Die Gesundheitskasse Tender

Contract notice: Conclusion of non-exclusive discount contracts according to § 130a para. 8 sgb v on medicinal products with the active ingredient sorafenib (l01ex02) as part of a so-called open-house model. Conclusion of non-exclusive discount contracts according to § 130a para. 8 sgb v on medicinal products with the active ingredient sorafenib (l01ex02) within the period from 01.12.2021 to 30.11.2023 with the possibility of concluding a contract at any time (open-house model).The aok rheinland-pfalz / saarland - die Gesundheitskasse offers discount contracts with the active ingredient sorafenib (l01ex02) to all interested pharmaceutical companies without making a selection. the contracts are concluded as part of an open house model . the contracts offered are not exclusive; Aok rheinland-pfalz / saarland - die Gesundheitskasse would like to have contracts with all market participants (pharmaceutical companies). In the open house model, uniform conditions apply to all participants. The content of the contract, terms and conditions and access procedures are uniform - individual negotiations are not carried out. The contract terms are a maximum of 24 months, the earliest contract start is December 01, 2021. All contracts end at the latest 24 months after the earliest start date, regardless of the date of the respective conclusion of the contract. A membership or a contract can be made within the 24-month period on the first of each month. There is a right of termination six weeks to the end of the month in accordance with the provisions of the contract. Further information on the termination options can be found in the contract documents. the aok rheinland-pfalz / saarland - the health insurance company reserves the right to replace the non-exclusive open-house discount contracts with exclusive discount contracts during the term of the contract as part of Europe-wide tendering procedures. With the entry into force of advertised, exclusive discount contracts, the open house contracts will be terminated in accordance with the contractual provisions, i.e. the open house contracts will end automatically. Interested pharmaceutical companies can request the participation documents and the contract documents from the contact address mentioned under i.1). Contracts for the active ingredient sorafenib (l01ex02) will be concluded for the first time with effect from December 01, 2021. Interested parties who would like to become a contractual partner on this date must submit the contract documents to the aok rheinland-pfalz / saarland - the health insurance company by October 31, 2021. it depends on the access at the aok rheinland-pfalz / saarland - the health insurance company. note: the first award in this procedure will be awarded at the earliest 10 calendar days after this eu notice has been published in the official gazette. Later contracts are possible during the twenty-four-month maximum term on the first of each month. In the case of interested part